Who, what, and when—effective therapy for severe COVID-19

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet. Rheumatology 2022-01, Vol.4 (1), p.e2-e3
Hauptverfasser:	Kelmenson, Daniel A, Cron, Randy Q
Format:	Artikel
Sprache:	eng
Schlagworte:	Comment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	e3
container_issue	1
container_start_page	e2
container_title	The Lancet. Rheumatology
container_volume	4
creator	Kelmenson, Daniel A Cron, Randy Q
description
doi_str_mv	10.1016/S2665-9913(21)00353-2
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8598210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2665991321003532</els_id><sourcerecordid>2601482297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-3eacf0640cce13054c63bb61e98d3dd36bc6d8d19d651466a2d6a6642fba9d5d3</originalsourceid><addsrcrecordid>eNqFkN1KAzEQhYMoVtRHUPZSwdVMskk3CIrUXxC88O8yZJNZG2l3a7KteOdD-IQ-iWtbi155NcPMmXOGj5AtoPtAQR7cMilFqhTwHQa7lHLBU7ZE1hbj5V99h2zG-EwpZQIAFF8lHZ7lwDIm1sjhY7_eS177ptlLTOXaDqvP9w8sS7SNn2DS9DGY0VtS1iGJOMGASe_m4eo0BbVBVkoziLg5r-vk_vzsrneZXt9cXPVOrlObyW6TcjS2pDKj1iJwKjIreVFIQJU77hyXhZUud6CcFJBJaZiTRsqMlYVRTji-To5mvqNxMURnsWqCGehR8EMT3nRtvP67qXxfP9UTnQuVM6Ctwc7cINQvY4yNHvpocTAwFdbjqJmkkOWMqW4rFTOpDXWMActFDFD9zV5P2etvsJqBnrLXrL3b_v3j4uqHdCs4ngmwJTXxGHS0HiuLzocWtXa1_yfiCxpnk7U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2601482297</pqid></control><display><type>article</type><title>Who, what, and when—effective therapy for severe COVID-19</title><source>Alma/SFX Local Collection</source><creator>Kelmenson, Daniel A ; Cron, Randy Q</creator><creatorcontrib>Kelmenson, Daniel A ; Cron, Randy Q</creatorcontrib><identifier>ISSN: 2665-9913</identifier><identifier>EISSN: 2665-9913</identifier><identifier>DOI: 10.1016/S2665-9913(21)00353-2</identifier><identifier>PMID: 34812425</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Comment</subject><ispartof>The Lancet. Rheumatology, 2022-01, Vol.4 (1), p.e2-e3</ispartof><rights>2022 Elsevier Ltd</rights><rights>2021 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-3eacf0640cce13054c63bb61e98d3dd36bc6d8d19d651466a2d6a6642fba9d5d3</citedby><cites>FETCH-LOGICAL-c467t-3eacf0640cce13054c63bb61e98d3dd36bc6d8d19d651466a2d6a6642fba9d5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34812425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kelmenson, Daniel A</creatorcontrib><creatorcontrib>Cron, Randy Q</creatorcontrib><title>Who, what, and when—effective therapy for severe COVID-19</title><title>The Lancet. Rheumatology</title><addtitle>Lancet Rheumatol</addtitle><subject>Comment</subject><issn>2665-9913</issn><issn>2665-9913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkN1KAzEQhYMoVtRHUPZSwdVMskk3CIrUXxC88O8yZJNZG2l3a7KteOdD-IQ-iWtbi155NcPMmXOGj5AtoPtAQR7cMilFqhTwHQa7lHLBU7ZE1hbj5V99h2zG-EwpZQIAFF8lHZ7lwDIm1sjhY7_eS177ptlLTOXaDqvP9w8sS7SNn2DS9DGY0VtS1iGJOMGASe_m4eo0BbVBVkoziLg5r-vk_vzsrneZXt9cXPVOrlObyW6TcjS2pDKj1iJwKjIreVFIQJU77hyXhZUud6CcFJBJaZiTRsqMlYVRTji-To5mvqNxMURnsWqCGehR8EMT3nRtvP67qXxfP9UTnQuVM6Ctwc7cINQvY4yNHvpocTAwFdbjqJmkkOWMqW4rFTOpDXWMActFDFD9zV5P2etvsJqBnrLXrL3b_v3j4uqHdCs4ngmwJTXxGHS0HiuLzocWtXa1_yfiCxpnk7U</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Kelmenson, Daniel A</creator><creator>Cron, Randy Q</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Who, what, and when—effective therapy for severe COVID-19</title><author>Kelmenson, Daniel A ; Cron, Randy Q</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-3eacf0640cce13054c63bb61e98d3dd36bc6d8d19d651466a2d6a6642fba9d5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Comment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kelmenson, Daniel A</creatorcontrib><creatorcontrib>Cron, Randy Q</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet. Rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelmenson, Daniel A</au><au>Cron, Randy Q</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Who, what, and when—effective therapy for severe COVID-19</atitle><jtitle>The Lancet. Rheumatology</jtitle><addtitle>Lancet Rheumatol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>4</volume><issue>1</issue><spage>e2</spage><epage>e3</epage><pages>e2-e3</pages><issn>2665-9913</issn><eissn>2665-9913</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34812425</pmid><doi>10.1016/S2665-9913(21)00353-2</doi><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2665-9913
ispartof	The Lancet. Rheumatology, 2022-01, Vol.4 (1), p.e2-e3
issn	2665-9913 2665-9913
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8598210
source	Alma/SFX Local Collection
subjects	Comment
title	Who, what, and when—effective therapy for severe COVID-19
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T00%3A49%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Who,%20what,%20and%20when%E2%80%94effective%20therapy%20for%20severe%20COVID-19&rft.jtitle=The%20Lancet.%20Rheumatology&rft.au=Kelmenson,%20Daniel%20A&rft.date=2022-01-01&rft.volume=4&rft.issue=1&rft.spage=e2&rft.epage=e3&rft.pages=e2-e3&rft.issn=2665-9913&rft.eissn=2665-9913&rft_id=info:doi/10.1016/S2665-9913(21)00353-2&rft_dat=%3Cproquest_pubme%3E2601482297%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2601482297&rft_id=info:pmid/34812425&rft_els_id=S2665991321003532&rfr_iscdi=true